Quality of Life, Urinary Tract Infection, Vaginal Infection
Conditions
Keywords
Pessary, Patient Satisfaction, Estrogen Cream
Brief summary
Patients presenting with pelvic organ prolapse will be offered the use of a pessary. Vaginal estrogen cream treatment with the pessary will be randomized amongst the patients and patient satisfaction and complication rates will be assessed during follow-up.
Detailed description
This will be a double-blinded, placebo-controlled, randomized controlled trial. Eligible patients presenting to the urogynaecology clinic with pelvic organ prolapse will be offered management with a pessary and participation in the study Patients who agree to participate in the study will be given a consent form Patients in the study and thus those who have opted for pessary use will be randomized between two groups: 1. Treatment group - will be given instructions for use and prescription for Premarin vaginal cream 2g at bedtime twice weekly 2. Control group - will utilize pessary with an inactive placebo cream Both the patient and the investigators will be blinded to patient treatment. If a patient has expressed willingness to participate in the study over the phone, the research assistant will issue a study number to the patient and pick up the corresponding cream from the LHSC pharmacy to give to the patient at their next clinic visit. The cream will be provided to the patient once they have read the letter of information and signed the consent form. For follow-up visits, the research assistant will monitor appointment bookings to ensure that the cream is ready in the clinic when the patient has their next follow-up visit. Patients of both groups will be fitted with a pessary. Pessary fitting will be individualized due to differences in pelvic size and shape and degree of prolapse. Patients may return to the clinic for subsequent fittings until a successful fit has been achieved. An unsuccessful fitting is defined as discontinued pessary use due to discomfort or expulsion. Patients will be assessed for satisfaction and complications 6 wks, 18 wks, 36 wks and 60 wks after the successful fitting. To determine patient satisfaction and complications, patients will complete a compilation of validated questionnaires assessing urinary symptoms, sexual function and quality of life at each follow-up. At each follow-up, a vaginal exam will be done and a vaginal swab and urine sample (for urinalysis and culture and sensitivities) will be taken to assess vaginal bleeding and infections.
Interventions
2g at bedtime twice weekly
DRUGPlacebo cream
2g at bedtime twice weekly
Sponsors
Academic Medical Organization of Southwestern Ontario
University of Western Ontario, Canada
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Any patient presenting to the clinic with pelvic organ prolapse will be offered management with a pessary and will be offered participation in the study.
Exclusion criteria
* have a contraindication to the use of estrogen cream or products * have any allergy to the use of estrogen cream or products * have a past medical or family history of breast cancer * have a past medical history of thromboembolism, myocardial infarction and stroke or are pregnant * have previously used Premarin vaginal cream * are currently using oral estrogen * are not competent to consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vaginal infections | 60 weeks | Vaginal swabs at each follow up visit will be used to detect presence or absence of vaginal infection. A total count of vaginal infections per patient will be compared between groups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of urinary tract infection | 60 weeks | Urine samples at each follow-up visit will be used to detect the presence or absence of a urinary tract infection. |
| Quality of life | 60 weeks | Patients will complete validated questionnaires to assess quality of life with respect to urinary, bowel, and sexual function. |
Countries
Canada
Outcome results
None listed